Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

News

 

GI Partners buys Charles River CDMO

American private equity firm GI Partners has agreed to acquire the contract development and manufacturing organisation (CDMO) and cell solutions businesses of Charles River Laboratories as part of a broader portfolio reshuffle by the global contract research organisation (CRO).

EQT drops takeover bid for Oxford Biomedica

Swedish private equity firm EQT has confirmed its intention to drop the takeover bid for UK-based Contract Development Manufacturing Organisation (CDMO) Oxford Biomedica (OXB).

2026 will see modest growth and selective mega deals — Interview with Matthew Edwards, Osborne Clarke

Healthcare and life sciences deal activity is expected to pick up in 2026, following trends seen in 2025 when the market remained steady despite regulatory challenges, according to a recent report from global law firm Osborne Clarke. HBI spoke to Matthew Edwards, Partner at Osborne Clarke, to explore these developments and what they could mean for healthcare and life sciences transactions in 2026.

Novartis sells Indian arm to PE as big pharma pivots to specialty medicines

Global pharma is increasingly viewing emerging markets in three segments, retaining operations hubs and premium specialty markets while exiting older, mass‑market generics. European companies are divesting legacy portfolios to focus on high-growth biologics and precision medicines.

Australian CRO SSR invests in Singapore’s Expecto Health Science 

Southern Star Research (SSR), an Australian clinical research organisation (CRO) backed by private equity firm Quadrant, has invested growth capital in Singapore-headquartered CRO Expecto Health Science. With this investment, the two CROs will form a strategic partnership to facilitate transition for sponsors from early-phase studies in Australia and New Zealand into late-phase clinical development across key Asian markets. 

Find Us